Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-10-051873
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-10-27 17:35:40
Reporting Period:
2010-10-27
Filing Date:
2010-10-27
Accepted Time:
2010-10-27 17:35:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1338042 Aegerion Pharmaceuticals Inc. AEGR Pharmaceutical Preparations (2834) 202960116
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1227759 Advent International Llc C/o Advent International Corporation
75 State Street, 29Th Floor
Boston MA 02109
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-10-27 1,249,350 $0.00 1,253,473 No 4 C Indirect See Footnote
Common Stock Acquisiton 2010-10-27 436,498 $0.00 1,689,971 No 4 C Indirect See Footnote
Common Stock Acquisiton 2010-10-27 805,140 $7.60 2,495,111 No 4 C Indirect See Footnote
Common Stock Acquisiton 2010-10-27 260,263 $9.50 2,755,374 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2010-10-27 3,228,204 $0.00 1,249,350 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2010-10-27 715,247 $0.00 436,498 $0.00
Common Stock Senior Subordinated Convertible Promissory Notes Disposition 2010-10-27 0 $0.00 805,140 $7.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 2011-12-31 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,123 Indirect See Footnote
Footnotes
  1. These securities are indirectly beneficially owned in the following capacities; as General Partner of AHLS III GP, which in turn is the General Partner of Advent Healthcare & Life Sciences III Limited Partnership and Advent Healthcare & Life Science III A Limited Partnership.
  2. Upon the closing of the Issuer's initial public offering on October 27, 2010, each share of Series A Convertible Preferred Stock (the "Series A Shares") and each share of the Series B Convertible Preferred Stock (the "Series B Shares"), plus accrued dividends, immediately converted into shares of common stock of the Issuer in accordance with the terms of the Issuer's Third Amended and Restated Certificate of Incorporation. The Series A Shares converted on a 1-for-0.38701117412 basis and the Series B Shares converted on a 1-for-0.61027657931 basis. The Series A Shares and the Series B Shares were convertible at any time, at the holder's election, and automatically upon consummation of the Issuer's initial public offering and had no expiration date.
  3. Shares acquired upon the closing of the Issuer's initial public offering at the initial public offering price of $9.50 per share.
  4. The outstanding principal and accrued and unpaid interest on these senior subordinated convertible promissory notes (the "Convertible Notes") automatically converted into shares of common stock upon the closing of the Issuer's initial public offering, at $7.60 per share, 80% of the Issuer's initial public offering price per share.